Sparsentan
Brand names: Filspari · Active ingredient: Sparsentan
In short: FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression . FILSPARI is indicated to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS)
What is Sparsentan used for?
FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression .
FILSPARI is indicated to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome .
âš Boxed warning (FDA's strongest warning)
Because of the risk of hepatotoxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Under the FILSPARI REMS, prescribers, patients, and pharmacies must enroll in the program .
Hepatotoxicity
Some Endothelin Receptor Antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver failure. In clinical studies, elevations in aminotransferases (ALT or AST) of at least 3-times the Upper Limit of Normal (ULN) have been observed in up to 3.5% of FILSPARI-treated patients, including cases confirmed with rechallenge.
Measure transaminases and bilirubin before initiating treatment and then every 3 months during treatment. Interrupt treatment and closely monitor patients who develop aminotransferase elevations more than 3-times ULN .
FILSPARI should generally be avoided in patients with elevated aminotransferases (>3-times ULN) at baseline because monitoring for hepatotoxicity may be more difficult and these patients may be at increased risk for serious hepatotoxicity .
Embryo-Fetal Toxicity
FILSPARI is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients. Therefore, in patients who can become pregnant, exclude pregnancy prior to initiation of FILSPARI.
Advise use of effective contraception before the initiation of treatment, during treatment, and for two weeks after discontinuation of treatment with FILSPARI. …
Sparsentan dosage
Prior to initiating treatment with FILSPARI, discontinue use of renin-angiotensin-aldosterone system (RAAS) inhibitors and endothelin receptor antagonists (ERAs) .
Initiate treatment with FILSPARI only after measuring aminotransferase levels and total bilirubin. Avoid initiation in patients with elevated aminotransferases greater than 3 times ULN. Continue required monitoring every 3 months during treatment with FILSPARI .
Exclude pregnancy before initiating treatment with FILSPARI .
The recommended dosing of FILSPARI in patients with IgAN and in patients with FSGS is described in Table 1.
When resuming treatment with FILSPARI in patients with IgAN or FSGS after an interruption, consider initiating at 50% of the recommended dose and titrating to the recommended dose after 14 days .
Indication | Starting Dose
(orally once daily for
14 days and increase
to recommended
dose, as tolerated) | Recommended Dose
(orally once daily)
IgAN (Adult Patients) | 200 mg | 400 mg
FSGS (Adults and Pediatric Patients 8 Years and Older)
Patients weighing greater
than 50 kg | 400 mg | 800 mg
Patients weighing less than
or equal to 50 kg | 200 mg | 400 mg
• Instruct patient to swallow tablets whole with water prior to the morning or evening meal.
• For patients who are unable to swallow whole tablets FILSPARI may be crushed and suspended in water immediately before administration prior to the morning or evening meal . Administration of FILSPARI with other liquids has not been studied and is not recommended.
• Preparation and Administration of FILSPARI Suspension in Water:
1. Crush the FILSPARI tablet in a clean pill crusher or mortar and pestle.
2. Suspend the crushed tablet in half cup of water and mix.
3. Orally administer the entire prepared suspension immediately. If any portion of the tablet is left in the cup, add little more water to the cup, swirl and swallow immediately.
4. Do not store suspension for later use. Take dose before the same meal each day.
• If a dose is missed, take the next dose at the regularly scheduled time. Do not take double or extra doses.
If aminotransferase levels increase, adjust monitoring and treatment plan according to Table 2.
Do not resume treatment in patients who have experienced clinical symptoms of hepatotoxicity or in patients whose hepatic enzyme levels and bilirubin have not returned to pretreatment levels.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; INR = international normalized ratio; ULN = upper limit of normal.
ALT/AST levels | Treatment and monitoring recommendations
Greater than 3 times and less than or equal to 8 times ULN | Confirm elevation with a repeat measure. …
How to take Sparsentan — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Medication Guide).
Restricted Access
Advise the patient that FILSPARI is only available through a restricted access program called the FILSPARI REMS because of the risk of hepatotoxicity, and that FILSPARI is available only from certified pharmacies that are enrolled in the FILSPARI REMS.
As a component of the FILSPARI REMS, prescribers must review the contents of the FILSPARI Medication Guide with the patient before initiating FILSPARI and patients must sign the FILSPARI REMS Patient Enrollment Form to confirm that they understand the risks of FILSPARI.
Instruct patients of the risk of hepatotoxicity associated with FILSPARI.
Hepatotoxicity
Advise patients with symptoms suggesting hepatotoxicity (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching) to immediately stop taking FILSPARI and seek medical attention .
Discuss with the patient the requirement to measure serum aminotransferases every 3 months . …
Warnings & precautions
Do not take this medicine if: Use of FILSPARI is contraindicated in patients who are pregnant [see Dosage and Administration (2.3), Warnings and Precautions (5.3), Use in Specific Populations (8.1)].
Do not co-administer FILSPARI with ARBs, ERAs, or aliskiren .
Elevations in ALT or AST of at least 3-fold ULN have been observed in up to 3.5% of FILSPARI-treated patients, including cases confirmed with rechallenge . While no concurrent elevations in bilirubin greater than 2-times ULN or cases of liver failure were observed in FILSPARI-treated patients in clinical trials, some endothelin receptor antagonists have caused elevations of aminotransferases, hepatotoxicity, and liver failure. To reduce the risk of potential serious hepatotoxicity, measure serum aminotransferase levels and total bilirubin prior to initiation of treatment and then every 3 months during treatment .
Advise patients with symptoms suggesting hepatotoxicity (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching) to immediately stop treatment with FILSPARI and seek medical attention. If aminotransferase levels are abnormal at any time during treatment, interrupt FILSPARI and monitor as recommended .
Consider re-initiation of FILSPARI only when hepatic enzyme levels and bilirubin return to pretreatment values and only in patients who have not experienced clinical symptoms of hepatotoxicity .
Avoid initiation of FILSPARI in patients with elevated aminotransferases (greater than 3-times ULN) because monitoring hepatotoxicity in these patients may be more difficult and these patients may be at increased risk for serious hepatotoxicity .
For all patients, FILSPARI is available only through a restricted program under a REMS called the FILSPARI REMS because of the risk of hepatotoxicity . …
Sparsentan side effects
Clinically significant adverse reactions that appear in other sections of the label include:
•Hepatotoxicity
•Embryo-Fetal Toxicity
•Hypotension
•Acute Kidney Injury
•Hyperkalemia
•Fluid Retention
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
IgAN
The safety of FILSPARI was evaluated in PROTECT (NCT03762850), a randomized, double-blind, active-controlled clinical study in adults with IgAN.
The data below reflect FILSPARI exposure in 202 patients with a median duration of 110 weeks.
The most common adverse reactions are presented in Table 3.
1 Includes related terms.
2 Elevations in ALT or AST greater than 3-fold ULN.
FILSPARI
(N = 202)
n (%) | Irbesartan
(N = 202)
n (%)
Hyperkalemia1 | 34 (17) | 27 (13)
Hypotension (including orthostatic hypotension) | 33 (16) | 13 (6)
Peripheral edema1 | 33 (16) | 29 (14)
Dizziness1 | 32 (16) | 14 (7)
Anemia | 16 (8) | 9 (4)
Acute kidney injury | 12 (6) | 5 (2)
Transaminase elevations2 | 7 (3.5) | 8 (4.0)
FSGS
The safety of FILSPARI was evaluated in DUPLEX (NCT03493685), a randomized, double-blind, active-controlled clinical study in adult and pediatric patients with FSGS . …
Drug interactions
Do not coadminister FILSPARI with ARBs, ERAs, or aliskiren .
Combined use of these agents is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure).
Avoid concomitant use of FILSPARI with strong CYP3A inhibitors. If a strong CYP3A inhibitor cannot be avoided, interrupt treatment with FILSPARI. When resuming treatment with FILSPARI, consider dose titration .
Monitor blood pressure, serum potassium, edema, and kidney function regularly when used concomitantly with moderate CYP3A inhibitors . No FILSPARI dose adjustment is needed.
Sparsentan is a CYP3A substrate. Concomitant use with a strong CYP3A inhibitor increases sparsentan Cmax and AUC , which may increase the risk of FILSPARI adverse reactions.
Avoid concomitant use with a strong CYP3A inducer. Sparsentan is a CYP3A substrate. Concomitant use with a strong CYP3A inducer decreases sparsentan Cmax and AUC , which may reduce FILSPARI efficacy.
Monitor for signs of worsening renal function with concomitant use with NSAIDs (including selective COX-2 inhibitors). …
About this medicine
FILSPARI (sparsentan) is an endothelin and angiotensin II receptor antagonist. The chemical name of sparsentan is 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide.
Sparsentan is a white to off-white powder, which is practically insoluble in water. Sparsentan has pH-dependent solubility, with intrinsic solubility of 1.48 and 0.055 mg/mL under pH 1.2 and 6.8, respectively. Sparsentan has a molecular weight of 592.76 g/mol, a molecular formula of C32H40N4O5S, and the following structure:
FILSPARI is available as film-coated 200 mg and 400 mg strength immediate release tablets for oral administration.
The inactive ingredients in FILSPARI are colloidal silicon dioxide, lactose anhydrous, magnesium stearate, silicified microcrystalline cellulose, and sodium starch glycolate. Film-coating is composed of macrogol/polyethylene glycol, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d7354af1-f304-f4d9-e053-2995a90ab219. Read the full official label on DailyMed.